11dehydroTXB2

11-Dehydrothromboxane B₂ (11-dehydroTXB₂) is a stable metabolite of thromboxane A₂ (TXA₂), a potent lipid mediator derived from arachidonic acid via the cyclooxygenase (COX) pathway. Thromboxane A₂ is a short-lived prostanoid that plays a critical role in platelet aggregation, vasoconstriction, and inflammation. Upon release, TXA₂ rapidly hydrolyzes into its inactive metabolite, 11-dehydroTXB₂, which can be measured in biological samples to assess TXA₂ production in vivo.

The formation of 11-dehydroTXB₂ occurs through enzymatic and non-enzymatic pathways. Initially, TXA₂ is converted into thromboxane B₂ (TXB₂) by hydration, and TXB₂ is further oxidized at the 11-position by 11-ketoreductase enzymes or through spontaneous oxidation. This metabolite is chemically stable, allowing for its detection in urine, plasma, and other biological matrices via immunoassays or mass spectrometry techniques.

11-DehydroTXB₂ serves as a biomarker for TXA₂-mediated physiological processes, particularly in cardiovascular and inflammatory diseases. Elevated levels of 11-dehydroTXB₂ have been associated with conditions such as atherosclerosis, hypertension, and acute coronary syndromes, where excessive TXA₂ activity contributes to thrombotic events. Additionally, its measurement helps in evaluating the efficacy of antiplatelet therapies, such as aspirin, which inhibit COX-1 and reduce TXA₂ synthesis.

In clinical research, 11-dehydroTXB₂ is often quantified alongside other eicosanoids, such as prostaglandins or prostacyclin metabolites, to provide a comprehensive profile of arachidonic acid metabolism. Its stability and ease of detection make it a valuable tool in both diagnostic and investigative settings. However, interpretation of its levels requires consideration of confounding factors, including diet, medication use, and individual variability in metabolic pathways.